Herbs (Global Traditional) · Native American
Goldenseal (Hydrastis canadensis) (Hydrastis canadensis)
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Goldenseal (Hydrastis canadensis) is a North American herb containing berberine, an isoquinoline alkaloid that exhibits antimicrobial and anti-inflammatory properties. The primary mechanisms involve inhibition of bacterial adhesion and modulation of inflammatory cytokines, though human clinical evidence remains limited.
Goldenseal (Hydrastis canadensis) is a perennial herb native to eastern North American woodlands, primarily harvested from its roots and rhizomes. The plant's active compounds are extracted using methods including Soxhlet extraction, aqueous acetonitrile, or HPLC, yielding benzylisoquinoline alkaloids like berberine, hydrastine, and canadine.
The research dossier reveals no specific human clinical trials, RCTs, or meta-analyses for goldenseal, with no PubMed PMIDs provided. Reviews emphasize the critical need for large randomized, double-blind clinical studies to confirm efficacy and safety, as current evidence remains primarily preclinical or traditional.
No clinically studied dosage ranges are available due to absence of human trials. USP standards require minimum 2.5% berberine and 2.0% hydrastine in dried roots/rhizomes, with commercial products varying widely (berberine 0.5-6.0%, hydrastine 1.5-4.0%). Consult a healthcare provider before starting any new supplement.
Goldenseal root and rhizome are not consumed as a food source and therefore lack a conventional macronutrient profile (negligible calories, protein, fat, and carbohydrates per typical dose of 0.5–2 g dried root). The primary value lies in its bioactive alkaloid content: • **Berberine** (~2.5–4.5% of dried root by weight, approximately 25–45 mg per gram of dried root) — an isoquinoline alkaloid responsible for most studied pharmacological effects; oral bioavailability is notably low (<5%) due to extensive first-pass metabolism and P-glycoprotein efflux, though gut-level antimicrobial activity may still occur. • **Hydrastine** (~2–4% of dried root) — the most abundant alkaloid in goldenseal; contributes vasoconstrictive and astringent properties; limited standalone pharmacological study. • **Canadine (tetrahydroberberine)** (~0.5–1.5%) — a minor alkaloid with mild sedative and smooth muscle relaxant properties. • **Berberastine and other minor alkaloids** (trace amounts <0.5%). • **Minerals**: trace amounts of iron, manganese, and calcium present in the root matrix, though quantities are nutritionally insignificant at typical dosages. • **Fiber**: small amounts of insoluble fiber from root material, negligible in extract/capsule forms. • **Polysaccharides and tannins**: present in modest concentrations, potentially contributing to mucous membrane astringency and mild prebiotic-like effects locally in the gut. • **No significant vitamin content** (no appreciable levels of vitamins A, C, D, E, K, or B-complex). • **Bioavailability notes**: Berberine's systemic bioavailability is extremely poor (~5%) but can be modestly enhanced by co-administration with P-glycoprotein inhibitors (e.g., piperine may increase absorption 2-fold in some studies). Hydrastine is somewhat better absorbed but undergoes rapid hepatic metabolism. Whole-root preparations may exhibit different pharmacokinetics than isolated alkaloid extracts due to synergistic or matrix effects among co-occurring alkaloids. Standardized extracts are typically normalized to 5–10% total alkaloid content (berberine + hydrastine combined).
Berberine, the primary bioactive alkaloid in goldenseal, inhibits bacterial growth by disrupting cell wall synthesis and preventing pathogen adhesion to host tissues. It modulates inflammatory responses by suppressing NF-κB activation and reducing pro-inflammatory cytokines like TNF-α and IL-6. Berberine also activates AMPK (adenosine monophosphate-activated protein kinase), which may contribute to glucose regulation and metabolic effects.
Most goldenseal research consists of in vitro and animal studies, with limited human clinical trials. Berberine studies show antimicrobial activity against various bacteria and fungi in laboratory settings. Small human studies on berberine (not specifically goldenseal) demonstrate blood glucose reductions of 15-25% in diabetic patients at doses of 500mg three times daily. However, no large-scale randomized controlled trials have specifically evaluated goldenseal's efficacy or safety in humans.
Goldenseal may cause digestive upset, skin irritation, and elevated blood pressure at high doses. It can inhibit cytochrome P450 enzymes, particularly CYP3A4 and CYP2D6, potentially altering the metabolism of medications including warfarin, cyclosporine, and certain antidepressants. Pregnant and breastfeeding women should avoid goldenseal due to potential uterine stimulation and lack of safety data. Long-term use may interfere with B-vitamin absorption and should be avoided without medical supervision.
